Publications
& Presentations

Data from this study underscore the potential of the Sunbird Platform to accurately and directly detect tau aggregation in the brain via blood test.

Data from this study suggest that the Sunbird Platform measures a pathologically relevant Aβ aggregate in blood circulation accurate to the amyoid deposition that PET measured in the brain.

Data from this study suggest that the Sunbird Platform outperforms a commercial Alzheimer’s disease blood test, with better correlation to amyloid PET.

Data from this landmark study show that the Sunbird Platform test has a 90% correlation to gold-standard PET, while all other blood-based diagnostic tests have a correlation of about 20%.

In this pilot biomarker study, the Glympse platform accurately differentiated hepatocellular carcinoma (HCC) from cirrhosis.

This study of two diverse cohorts of patients with known HCC vs. healthy controls showed that the Glympse platform was highly effective at detecting HCC.